FDA Approval: 1L Amivantamab Plus Chemotherapy for EGFR Exon 20 NSCLC

Podcast | English | 2024 | 28 Min

Create Account

Cost

$0.00

Credit

No Credit Offered

In this episode of Lung Cancer Considered, host Dr. Stephen Liu leads a discussion on the FDA approval of first-line amivantamab plus chemotherapy for NSCLC with an EGFR exon 20 insertion based on the phase III PAPILLON trial. These data were first shared at ESMO 2023 in Madrid with a simultaneous publication in the New England Journal of Medicine.

Podcast Hosts:

Stephen Liu, MD, Associate Professor of Medicine, Director of Thoracic Oncology and Director of Developmental Therapeutics, Georgetown Lombardi Comprehensive Cancer Center, Washington, D.C., USA

Podcast Guests:

Michael Boyer, MD, Professor and Kam Ling Barbara Lo Chair in Lung and Thoracic Cancer at the University of Sydney, and CEO of Chris O'Brien Lifehouse, Sydney, Australia
Angel Qin, Clinical Assistant Professor adn Co-Chair of the Thoracic Clinical Research Team, University of Michigan Rogel Cancer Center, Ann Arbor, MI, USA